QPPV.COM KNOWLEDGE ASSESSMENT

EU Pharmacovigilance Inspection Findings: Benefit–Risk Assessment and Decision-Making

Test your understanding of the concepts covered by EU Pharmacovigilance Inspection Findings: Benefit–Risk Assessment and Decision-Making.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Why is a clearly defined decision question important in a material safety assessment?

It ensures that every possible data source is included It determines which evidence and outcomes are relevant to the assessment It removes the need for expert scientific judgement It guarantees that the final decision will result in regulatory action

Question 2 of 10 Why should internal self-inspection sample decisions that resulted in no action?

No-action decisions are exempt from governance and therefore easy to review They test whether the organisation can demonstrate that continued monitoring or no change was justified They are always higher risk than decisions involving regulatory action They provide evidence that no safety concern existed

Question 3 of 10 An organisation performs a current reassessment of a safety issue and uses it as the sole justification for a decision made five years earlier. What is the main inspection concern?

Scientific assessments may never be updated The organisation is using hindsight rather than demonstrating what information and procedure applied at the historical time A historical decision is automatically invalid if the current conclusion differs Current evidence is never relevant to inspection

Question 4 of 10 What is the QPPV's appropriate role in relation to material benefit–risk decisions?

Personally perform every scientific assessment Approve every individual case report before processing Maintain appropriate oversight and visibility and have sufficient access and authority to escalate concerns Replace the competent authority in making regulatory decisions

Question 5 of 10 Which overall principle best summarises the article's inspection perspective on benefit–risk decision-making?

Inspectors should determine the single scientifically correct interpretation of every safety dataset The existence of regulatory action is the primary evidence that a pharmacovigilance system is effective The organisation should demonstrate a controlled, evidence-based and appropriately governed path from information to decision, action and reassessment A decision is defensible only when all experts agree and all uncertainty is eliminated

Question 6 of 10 When a risk-minimisation measure is selected, which linkage should the organisation be able to explain?

How the measure was selected in relation to the identified risk and how its intended effect will be evaluated Why the measure eliminates the underlying risk completely Why effectiveness evaluation is unnecessary once implementation is documented Why the most restrictive available measure must always be used

Question 7 of 10 Which statement most accurately describes the inspection significance of uncertainty?

Any uncertainty proves that the assessment is inadequate Uncertainty is acceptable when it is recognised, evaluated and appropriately managed within the decision process Uncertainty should be excluded from decision records to avoid regulatory concern Uncertainty permits the organisation to bypass applicable governance

Question 8 of 10 Which statement best distinguishes a signal assessment from a broader benefit–risk decision?

A signal assessment always determines whether the product should be withdrawn A benefit–risk decision considers the safety concern in the context of therapeutic benefits, alternatives and other relevant factors A signal assessment is limited to clinical-trial data, whereas benefit–risk decisions use spontaneous reports only A benefit–risk decision can be made only after a signal has been confirmed

Question 9 of 10 A serious emerging concern has incomplete evidence, but waiting for definitive data could delay protection of patients. Which approach is most consistent with the article?

Take no action until causality is proven Make a proportionate decision that recognises uncertainty, such as interim risk management, escalation or continued monitoring with evidence generation Treat the concern as confirmed solely because it is serious Avoid documenting uncertainty because urgent decisions should be simple

Question 10 of 10 Which evidence package would best support reconstruction of a material safety decision during inspection?

A current summary prepared by an employee who was not involved in the original decision The triggering information, contemporaneous assessment, governance record, decision rationale, action records and relevant follow-up A revised procedure showing how similar decisions should be made today Training attendance records for the assessors

EU Pharmacovigilance Inspection Findings: Benefit–Risk Assessment and Decision-Making

Cookie Settings